Cargando…
Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma
Despite the clinical benefit of the proteasome inhibitor bortezomib, multiple myeloma (MM) patients invariably relapse through poorly defined mechanisms. Myeloma cells inevitably develop chemoresistance that leads to disease relapse and patient-related deaths. Studies in tumor cell lines and biopsie...
Autores principales: | Abdel Malek, Mohamed A.Y., Jagannathan, Sajjeev, Malek, Ehsan, Sayed, Douaa M., Elgammal, Sahar A., Abd El-Azeem, Hanan G., Thabet, Nabila M., Driscoll, James J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413640/ https://www.ncbi.nlm.nih.gov/pubmed/25605012 |
Ejemplares similares
-
Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells
por: Jaganathan, Sajjeev, et al.
Publicado: (2014) -
Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib
por: Jagannathan, S, et al.
Publicado: (2015) -
Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer
por: Malek, Ehsan, et al.
Publicado: (2014) -
MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib
por: Jagannathan, S, et al.
Publicado: (2015) -
The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection
por: Carlos, Anthony J., et al.
Publicado: (2021)